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ABSTRACT
The proteasome inhibitor bortezomib has proven to be invaluable in the treatment 
of myeloma. By exploiting the inherent high immunoglobulin protein production of 
malignant plasma cells, bortezomib induces endoplasmic reticulum (ER) stress and 
the unfolded protein response (UPR), resulting in myeloma cell death. In most cases, 
however, the disease remains incurable highlighting the need for new therapeutic 
targets. Sphingosine kinase 2 (SK2) has been proposed as one such therapeutic target 
for myeloma. Our observations that bortezomib and SK2 inhibitors independently 
elicited induction of ER stress and the UPR prompted us to examine potential synergy 
between these agents in myeloma. Targeting SK2 synergistically contributed to ER 
stress and UPR activation induced by bortezomib, as evidenced by activation of the 
IRE1 pathway and stress kinases JNK and p38MAPK, thereby resulting in potent 
synergistic myeloma apoptosis in vitro. The combination of bortezomib and SK2 
inhibition also exhibited strong in vivo synergy and favourable effects on bone 
disease. Therefore, our studies suggest that perturbations of sphingolipid signalling 
can synergistically enhance the effects seen with proteasome inhibition, highlighting 
the potential for the combination of these two modes of increasing ER stress to be 
formally evaluated in clinical trials for the treatment of myeloma patients.
INTRODUCTION
Myeloma is a relatively common and incurable 
malignancy of plasma cells with an age-adjusted incidence 
of six per 100 000 per year in the USA and Europe [1]. 
Despite recent advances in therapy and supportive care, 
the median overall survival is 6 years [1]. In recent 
years, the introduction of the 26S proteasome inhibitor 
bortezomib into multi-drug treatment regimes has 
dramatically improved remission rates, however, disease 
relapse inevitably occurs [2, 3]. Myeloma cells produce 
and secrete large quantities of immunoglobulin, which 
requires folding within the endoplasmic reticulum (ER). 
The development of ER stress occurs when misfolded 
proteins accumulate and overwhelm the folding capacity 
of the ER. This results in the initiation of adaptive 
homeostatic processes, including expansion of ER protein 
chaperone and folding capacity, removal of misfolded 
proteins from the ER for proteasomal degradation, a 
process termed ER-associated degradation (ERAD), and 
activation of the so-called unfolded protein response 
(UPR) [4]. The UPR is initiated when the accumulation 
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of misfolded proteins results in the dissociation of 
the ER chaperone binding immunoglobulin protein 
(BiP) from the lumenal domains of the three ER stress 
transmembrane protein sensors: protein kinase R-like 
ER kinase (PERK), inositol-requiring kinase 1 (IRE1) 
and activating transcription factor 6 (ATF6) [4, 5]. From 
each of these UPR initiating proteins, a cascade of protein 
interactions ensues, with the net result being an expansion 
of ER folding capacity, a reduction in protein generation 
and hence the entry of nascent proteins into the ER, and 
enhanced clearance of unfolded proteins via ERAD. 
However, if ER stress continues for a prolonged period, 
the generally pro-survival adaptive measures cease and 
sustained UPR activation results in expression of the pro-
apoptotic transcription factor CHOP (CCAAT/enhancer 
binding protein (C/EBP) homologous protein) and 
induction of cell death [6]. By exploiting the sensitivity 
of myeloma cells to ER stress, proteasome inhibition 
by bortezomib produces sustained UPR activation that 
ultimately results in myeloma cell death [7].
Sphingosine kinase 2 (SK2) is one of two SK 
isoforms that catalyses the phosphorylation of sphingosine 
to sphingosine 1-phosphate (S1P), a sphingolipid 
implicated in cancer growth and survival [8]. SK2 is 
found in discrete subcellular locations including the ER 
and nucleus, the latter shown to be involved in Myc 
transcription in acute lymphoblastic leukaemia (ALL) 
with inhibition of SK2 exhibiting anti-leukaemic efficacy 
[9, 10]. More recently, inhibition of SK2 has shown some 
efficacy as a monotherapy in a pre-clinical myeloma 
study, although the mechanisms for these effects were not 
well defined [11]. In the current study, we show that SK2 
inhibition has anti-myeloma activity by inducing ER stress 
and activating the UPR. Furthermore, combining SK2 
inhibition with low dose bortezomib produced synergistic 
ER stress and UPR activation that potently induced 
apoptosis associated with activation of the stress kinases 
c-Jun N-terminal kinase (JNK) and p38 mitogen-activated 
protein kinase (p38MAPK) that are known to associate 
with the IRE1 arm of the UPR [12, 13]. Finally, we found 
that this dual therapeutic strategy synergistically reduced 
disease burden in an aggressive immunocompetent murine 
model of myeloma, raising the potential to progress such a 
therapeutic strategy towards clinical trials for the treatment 
of human myeloma.
RESULTS
Sphingosine kinase 2 as a target in multiple 
myeloma
Elevated expression of SK2 has been demonstrated 
previously in newly diagnosed myeloma patient CD138+ 
cells compared to plasma cells from healthy normal 
individuals [11]. To assess these findings in more 
detail, we examined the expression levels of SK2 and 
other genes involved in sphingolipid biosynthesis, in a 
different, larger dataset comprised of gene expression 
data from CD138+ bone marrow plasma cells from 
newly diagnosed myeloma patients compared to normal 
healthy controls [14]. Notably, this analysis revealed 
that numerous genes critical to sphingolipid synthesis 
and metabolism to S1P were significantly elevated in 
myeloma, including serine palmitoyl transferase 1, 
3-ketodihydrosphingosine reductase, ceramide synthases 
2 and 5, sphingomyelinase 2, and alkaline ceramidase 3 
(Figure 1A and Supplementary Figure 1), supporting the 
notion that sphingolipid metabolism is dysregulated in 
myeloma. Further gene set enrichment analysis failed to 
find enrichment of gene sets associated with sphingolipid 
synthesis or metabolism in MGUS or myeloma patients 
compared to normal healthy controls using this dataset. 
However, the changes in gene expression of the various 
enzymes in this pathway indicates a general increase 
in de novo ceramide synthesis, suggesting increased 
dependency on sphingosine kinases to metabolise the 
resultant ceramide. While plasma cell expression of 
SK1 was similar between healthy normal individuals, 
patients with monoclonal gammopathy of undetermined 
significance (MGUS) and myeloma, the expression of SK2 
was significantly increased (P < 0.001, Kruskal-Wallis 
test) in myeloma patients compared with healthy normal 
age matched controls (Figure 1B). 
Next, we compared the expression levels of SK1 and 
SK2 in a range of human myeloma cell lines. Consistent 
with previous studies using other myeloma cell lines 
[11], both RT-qPCR and isoform-selective enzyme assays 
revealed much higher SK2 levels compared to SK1 in 
almost all cell lines examined (Figure 1C). Taken together, 
these data suggest SK2 is more relevant than SK1 in 
myeloma and represents a potential therapeutic target.
Previous studies examining the targeting of SK2 
in myeloma employed ABC294640 [11], a SK2 inhibitor 
that has been recently shown to display off target effects 
by more potently inhibiting dihydroceramide desaturase 
[15, 16]. Thus to validate the effect of inhibiting SK2 in 
myeloma we treated human myeloma cell lines with a 
different, more potent SK2-selective inhibitor, K145 [17], 
which we established does not inhibit dihydroceramide 
desaturase (Supplementary Figure 2). K145 resulted 
in myeloma cell death at 24 h with IC50 values of 3 to 
7 µM as determined by Annexin V/PI staining and flow 
cytometry (Figure 2A). Consistent with a previous report 
[11], dose- and time-dependent myeloma cell death was 
also observed with ABC294640 (Supplementary Figure 
3) with IC50 values at 24 h being significantly higher 
than those measured at later timepoints (P < 0.001, 
ANOVA with repeated measures), further suggesting 
that inhibition of SK2 has anti-myeloma activity. K145-
induced cell death was dose-dependent, corresponded to a 
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progressive reduction in cell viability and was associated 
with caspase-3 cleavage (Figure 2B). This cell death was 
largely prevented upon pre-incubation of myeloma cells 
with the pan-caspase inhibitor Z-VAD-FMK prior to 
the addition of K145, indicative of a caspase-dependent 
process and classical apoptosis (Figure 2C). As ceramides, 
upstream of SK2 action, are generally associated with 
apoptosis [18], we confirmed that K145 was associated 
with loss of S1P and the accumulation of long-chain 
(C14-C22) ceramides (Figure 2D and Supplementary 
Figure 4).
Blockade of sphingosine kinase 2 synergises with 
bortezomib to induce myeloma cell death
Since the proteasome inhibitor bortezomib is 
a current front-line therapy for myeloma, we next 
examined the effect of treating myeloma cell lines with 
K145 in combination with bortezomib. Strikingly, 
combinations of minimally cytotoxic concentrations 
of bortezomib with K145 resulted in strong synergistic 
cell death in LP-1 (Figure 3A), 5TGM1 (Figure 3C) 
Figure 1: SK2 has higher expression than SK1 in myeloma. A. Expression (log2) of sphingolipid enzymes in the publically 
available gene expression dataset E-MTAB-363 [14] of purified CD138+ bone marrow plasma cells from normal healthy (n = 5), MGUS 
(n = 5) and myeloma (n = 155) patients. The heatmap shows log2-fold changes where strong evidence existed (P < 0.01, Kruskal-Wallis 
test) for different median gene expression between normal and myeloma patients. All genes analysed are listed, but genes lacking strong 
evidence for differential expression (P > 0.01) are indicated with white boxes. B. Analysis of E-MTAB-363 demonstrates no change in 
SK1 (SPHK1) as disease progresses whereas SK2 (SPHK2) increases significantly between normal and MM (*P = 0.0004, Kruskal-Wallis 
test). Signal intensity represents log2 gene expression. C. SK1 and SK2 gene expression was analysed by RT-qPCR in the indicated human 
myeloma cell lines (upper) showing greater SK2 expression in all but one cell line examined. Enzyme activity assay for SK1 and SK2 using 
human myeloma cell lines (lower) reveals SK2 is more active than SK1 in most cell lines. Data are mean±SD of triplicate measurements 
and are representative of three independent experiments.
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and H929 (Supplementary Figure 5) human and mouse 
myeloma cell lines. These synergistic drug interactions 
were demonstrated by the fractional product method 
[19] with values less than -0.1 consistent with synergy 
and were confirmed by application of the combinatorial 
index (Supplementary Table 1). K145 also synergistically 
enhanced the efficacy of bortezomib in LP-1 cells, 
supporting the clinical potential of this combinatorial 
strategy (Figure 3B and Supplementary Table 2). 
Notably, combination drug treatment of 5TGM1 cells was 
associated with caspase-3 cleavage consistent with our 
observations in human myeloma cells (Supplementary 
Figure 6A). The alternative SK2 inhibitor, ABC294640, 
was used to confirm the synergistic effects of targeting 
SK2 in combination with bortezomib in LP-1 cells. 
Although relatively high ABC294640 concentrations were 
required to elicit cell death, a synergistic reduction in cell 
viability was again observed with bortezomib (Figure 3D 
and Supplementary Table 1).
To confirm that the synergy between K145 and 
bortezomib was due to inhibition of SK2, we next assessed 
the effect of SK2 knockdown, using LP-1 cells expressing 
Figure 2: K145 induces myeloma cell death. A. The indicated human myeloma cell lines were cultured with increasing concentrations 
of K145 for 24 h and cell viability measured by flow cytometry using Annexin-V and PI staining with dual negative cells considered viable. 
B. LP-1 cells were treated for 16 h with the indicated concentrations of K145 and caspase-3 cleavage determined by intracellular flow 
cytometry. C. LP-1 (upper) and H929 (lower) cells were cultured with 10 µM or 4 µM, respectively, of K145 or vehicle, with or without 
pre-incubation with 100 µM Z-VAD-FMK and viability assessed after 16 h by flow cytometry. D. Sphingolipidomic analysis showing 
reduced S1P and increased long chain ceramide species in LP-1 cells treated with 8 µM K145 for 6 h. Data are mean±SD of duplicate 
measurements and are representative of three independent experiments. * P < 0.05.
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doxycycline-inducible SK2 shRNA and red fluorescent 
protein (RFP), in combination with low-dose bortezomib. 
Following 3 days of doxycycline induction, over 95% 
of the cells were RFP positive and SK2 knockdown was 
confirmed by RT-qPCR and SK2 activity assays (Figure 
4A). Knockdown of SK2 alone resulted in a reduction in 
cell proliferation, an effect that was further significantly 
enhanced by concomitant proteasome inhibition with 
bortezomib (P < 0.001, Figure 4B).
Bortezomib enhances ER stress induced by 
sphingosine kinase 2 inhibition and produces a 
terminal UPR
Myeloma cells are known to have elevated basal ER 
stress and activation of the UPR [4]. Analysis of a panel of 
human myeloma cell lines for several markers of ER stress 
and the UPR, including the ER chaperone BiP, XBP1s and 
phosphorylated eIF2α (p-eIF2α), showed marked variation 
in their basal expression (Figure 5A), implying differential 
sensitivities to proteasome inhibitors between myeloma 
cells. The ATF6 protein was not detectable in three of the 
human myeloma cell lines tested (LP-1, H929 and OPM2) 
and was not analysed further.
By inhibiting the proteasome, bortezomib has been 
shown to induce sufficient ER stress to activate pro-
apoptotic UPR signalling [7]. ER stress-induced activation 
of the endoribonuclease domain of the ER transmembrane 
protein, IRE1, splices an intron from precursor XBP1 
mRNA (XBP1u) that results in translation of the active 
transcription factor XBP1s [20, 21], levels of which have 
been shown to correlate with sensitivity to bortezomib 
in myeloma patients [22]. While bortezomib induces 
classical ER stress [7], the ER stress-inducing potential 
of SK2 inhibition was unknown. Notably, however, SK2 
can localise to the ER [9, 10], and ceramide, a major pro-
apoptotic lipid upstream of sphingosine kinase action has 
been widely implicated in inducing ER stress, mostly in 
non-cancer settings [23-25]. To examine the levels of ER 
stress and UPR activation in response to either bortezomib 
or K145 alone, LP-1 cells were exposed to increasing 
concentrations of either drug and assessed for several 
ER stress and UPR markers (Figure 5B). Consistent with 
Figure 3: SK2 inhibition synergises with bortezomib. A. LP-1 cells were cultured with the indicated concentrations of K145 with 
and without 6 nM bortezomib for 24 h and cell viability measured by flow cytometry using Annexin-V/PI staining. Predicted additive 
effects, calculated by the fractional product method [19], are shown by the dashed lines whilst actual observed combinational effects by 
the red lines. B. LP-1 cells were cultured with the indicated concentrations of bortezomib with and without 4 µM K145 for 24 h and cell 
viability measured by flow cytometry using Annexin-V/PI staining. C. 5TGM1 cells were cultured with the indicated concentrations of 
K145 with and without 4 nM bortezomib for 24 h and cell viability measured by flow cytometry using Annexin-V/PI staining. D. LP-1 cells 
were cultured with the indicated concentrations of ABC294640 with and without 6 nM bortezomib for 24 h and cell viability measured by 
flow cytometry using Annexin-V/PI staining. Predicted additive and observed combinational effects are shown by the dashed and red lines, 
respectively. Mean±SD of duplicate measurements shown. Data are representative of three independent experiments. 
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Figure 4: Genetic knockdown of SK2 recapitulates SK2 inhibition using K145. A. LP-1 cells were strongly RFP positive 
after 72 h of culture with 0.5 µg/mL doxycycline (dox) consistent with stable integration of the tetracycline inducible SK2 shRNA into 
the cell genome. SK2 gene expression and activity were reduced by 65% and 75%, respectively, in LP-1 cells exposed to the indicated 
concentrations of dox for 72 h. Mean±SD of triplicate measurements are shown. B. LP-1 SK2 shRNA inducible cells were treated with 0.5 
µg/mL dox for 72 h and 4 nM bortezomib added for the final 24 h of culture. Cell proliferation was measured by WST-1 assay. Reduced SK2 
expression and activity results in a 52% reduction in proliferation which was further enhanced by the addition of bortezomib. Mean±SD of 
quadruplicate measurements shown. Data are representative of at least three independent experiments. * P < 0.05.
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previous reports, bortezomib induced a classical ER stress 
signalling profile with dose-dependent increases in BiP, 
XBP1s and p-eIF2α observed at relatively long timepoints 
(16 hours). SK2 inhibition by K145 also induced ER 
stress as indicated by dose-dependent increases in XBP1s 
and p-eIF2α. However, in contrast to bortezomib, BiP 
increased to a lesser degree in response to K145 (Figure 
5B), a finding also seen in a second human myeloma cell 
line, OPM2 and the murine myeloma cell line, 5TGM1 
(Supplementary Figures 6B, 7A and 7B). Consistent with 
prolonged ER stress, both bortezomib and K145 induced 
expression of the transcription factor CHOP downstream 
of p-eIF2α (Figure 5B). Interestingly, increased expression 
of IRE1α and modest activation of the apoptosis inducing 
stress kinase JNK were also observed with both agents 
(Figure 5B and Supplementary Figure 7C). Since 
induction of ER stress is likely an early event in response 
to these drugs, similar experiments performed at the early 
time point of 4 hours, prior to measurable cell death, 
demonstrated expression of ATF4 downstream of p-eIF2α 
and XBP1s with both bortezomib and K145 (Figure 5C 
and Supplementary Figure 7A).
In view of the observation that like bortezomib, the 
SK2 inhibitor K145 induced ER stress, we next assessed 
the potential for K145 to synergise with bortezomib to 
enhance ER stress in myeloma cells. The combination of 
individually sub-cytotoxic concentrations of bortezomib 
and K145 resulted in early synergistic expression of BiP, 
ATF4 and XBP1s (Figure 6A) with synergistic increases 
in BiP, XBP1s, p-eIF2α and CHOP detectable at later 
time points, consistent with strong induction of ER stress 
and UPR activation (Figure 6B). Similar findings were 
obtained using OPM2 and 5TGM1 cells (Supplementary 
Figures 6C, 7A and 7B), although in these cell lines, 
dephosphorylation of eIF2α was observed with the 
combination of both agents at longer culture times which 
occurs in the setting of chronic, unrecoverable ER stress 
and subsequent initiation of cell death [26]. However 
ATF4, which is downstream of p-eIF2α, was increased 
in OPM2 cells, clearly demonstrating activation of this 
pathway (Supplementary Figure 7A). As XBP1s protein 
is expressed early after the initiation of ER stress and is 
degraded rapidly in response to its chronicity [27], PCR 
was used to overcome difficulties in detecting XBP1s at 
later time points. RT-qPCR revealed a modest decrease in 
XBP1u and no significant increase in XBP1s following 16 
h treatment with either bortezomib or K145 alone (Figure 
6B). However, the combination of the two drugs resulted 
in a 2.5-fold increase in XBP1s. Additionally, a 2.4-fold 
increase in CHOP expression was observed at 16 h with 
the sub-cytotoxic concentration of bortezomib, whilst the 
sub-cytotoxic concentration of K145 did not significantly 
Figure 5: Bortezomib and K145 individually induce ER stress. A. ER stress and UPR proteins were assessed in a range of 
human myeloma cell lines and the 5TGM1 murine myeloma cell line. β-actin was used as a loading control. B. LP-1 cells were exposed to 
increasing concentrations of either bortezomib or K145 for 16 h and examined by Western blot for ER stress and UPR proteins. α-tubulin 
was used as a loading control. The viabilities for bortezomib conditions were 92%, 90%, 86%, 67%, 58% and 51%, whilst those for K145 
were 91%, 88%, 84%, 78% and 68%, respectively. RT-qPCR analysis for CHOP was performed in parallel and presented as a bar chart 
below the Western blots. Mean±SD of triplicate measurements shown. Data are representative of three independent experiments. C. LP-1 
cells were exposed to increasing concentrations of either bortezomib or K145 for 4 h and examined by Western blot for ER stress and UPR 
proteins. α-tubulin was used as a loading control. The viabilities for all conditions were greater than 85%.
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alter expression, as expected (Figure 6B). Consistent with 
the synergistic cell death seen when combining K145 
with bortezomib, a synergistic 19-fold increase in CHOP 
expression was detected at 16 h (Figure 6B). Furthermore, 
the combination of bortezomib with K145 at various 
sub- or minimally cytotoxic concentrations resulted in 
a synergistic increase in IRE1α expression, which was 
associated with activation of the stress kinases JNK and 
p38MAPK (Figure 6C and Supplementary Figure 7C). 
Similar synergistic induction of ER stress, as shown by 
increases in XBP1s and ATF4, was also observed with 
sub-cytotoxic doses of bortezomib in combination with 
the alternate SK2 inhibitor, ABC294640 (Supplementary 
Figure 8). Taken together, these data suggest that 
combining proteasome and SK2 inhibition results in 
synergistic ER stress and a terminal UPR that is associated 
with activation of stress kinases and subsequent apoptosis 
(Figure 6D).
Figure 6: Dual bortezomib and K145 treatment induces synergistic ER stress. A. LP-1 cells were cultured with vehicle and 
sub-cytotoxic concentrations of bortezomib (5 nM), K145 (7 µM) or both for 4 h and examined for levels of ER stress and UPR activation 
by Western blot. B. LP-1 cells were cultured with vehicle and sub-cytotoxic concentrations of bortezomib (3 nM), K145 (4 µM) or both 
for 16 h and examined for levels of ER stress and UPR activation by Western blot. Co-administration of bortezomib and K145 to LP-1 
cells increases expression of spliced XBP1 mRNA and produces a marked increase in CHOP gene expression by RT-qPCR at 16 h shown 
as bar charts below the Western blots. Mean±SD of triplicate determinations are shown with expression levels relative to control cultures 
and normalised to GAPDH. C. LP-1 cells were cultured with the indicated concentrations of bortezomib and K145 for 16 h. Levels of 
IRE1α and stress kinase activation were assessed by Western blot. α-tubulin was used as a loading control. D. Proposed schematic of how 
bortezomib and K145 combine to induce synergistic ER stress and UPR activation that results in pro-apoptotic IRE1α signalling.
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K145 synergises with bortezomib in an aggressive 
murine myeloma model
Since synergistic cell death was also observed in 
5TGM1 murine myeloma cells treated with bortezomib 
and K145 (Figure 3C), we next examined the effects 
of combinations of bortezomib and K145 in vivo. The 
5TGM1 C57BL/KaLwRij murine model of myeloma 
recapitulates aggressive human myeloma in an 
immunocompetent setting, with the rapid development of 
bone marrow failure and lytic bone lesions necessitating 
a relatively short (4-week) experimental design [28-34]. 
C57BL/KaLwRij mice were injected with 1 million 
Figure 7: Dual bortezomib and K145 therapy shows in vivo efficacy in the aggressive C57BL/KaLwRij murine myeloma 
model. A. Representative bioluminescence images of mice in each treatment group after luciferin injection at day 14 (pre-treatment), day 
21 (after one week of treatment) and day 28 (after two weeks of treatment). B. Quantitation of myeloma disease burden in each treatment 
group at day 28. Disease burden at each timepoint was modelled using a multiple linear regression that takes into consideration varying 
baseline (day 14) disease levels between animals. Mean disease burden ± 95% confidence interval for the mean are shown. 13 (7 male, 6 
female), 13 (7 male, 6 female), 13 (7 male, 6 female) and 15 (9 male, 6 female) mice were analysed from the control, bortezomib, K145 
and combination treatment groups, respectively. C. Mice were treated for three weeks (days 14 to 35) indicated by the shaded region and 
then monitored for clinical deterioration and culled as required. Kaplan-Meier survival functions for each treatment group are shown (P = 
0.0085, log-rank test).
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5TGM1 cells and disease was allowed to develop for 
two weeks before administration of bortezomib and/or 
K145. Disease burden was assessed by bioluminescence 
imaging after luciferin injection at baseline (day 14), after 
one week of treatment (day 21) and after two weeks of 
treatment (day 28) (Supplementary Figure 9). The 0.5 
mg/kg dose of bortezomib was chosen as it approximates 
the 1.3 mg/m2 dose administered to patients [35]. In a 
pilot study, K145 was administered daily at 40 mg/kg 
daily which, while resulting in significant reductions in 
disease burden compared to vehicle treated controls, mice 
exhibited signs of toxicity including lethargy, reduced food 
intake and weight loss. Thus, doses of K145 were reduced 
to 20 mg/kg in order to both reduce toxicity, and also to 
have minimal anti-myeloma effect so that the question of 
in vivo synergy with bortezomib could be evaluated.
Administration of 0.5 mg/kg bortezomib as a 
monotherapy, three times per week for two weeks, resulted 
in a modest reduction in myeloma burden, consistent with 
previous reports [29, 30, 35]. Daily administration of 
20 mg/kg K145 as a monotherapy, for two weeks, also 
gave a modest reduction in myeloma burden, supporting 
the findings of a previous study using an alternative, 
poorly selective SK2 inhibitor, ABC294640 [11]. The 
combination of bortezomib and K145, however, resulted 
in a remarkable synergistic reduction in myeloma burden 
(Figure 7A and 7B), with vehicle control mice possessing 
31 times more disease than mice receiving both drugs (P 
< 0.001, 95% CI 10.82-87.61). Mice receiving single drug 
therapy did not lose weight, nor manifest any signs of 
drug toxicity, compared to vehicle controls whilst a small, 
non-significant reduction in weight was observed in mice 
receiving both drugs (mean weight reduction 1.8±0.5 g, P 
= 0.192). Furthermore, when treatment was extended for 
an additional week to where clinical deterioration enabled 
a survival profile to be obtained, mice receiving both 
bortezomib and K145 showed a median 12-day extension 
in survival (median survival 46 days, 95% CI 33 days 
to 58 days) compared to vehicle control mice (median 
survival 34 days, 95% CI 28 days to 39 days) (Figure 7C).
Figure 8: Dual bortezomib and K145 therapy has favourable effects on myeloma bone disease. A. Representative micro 
CT scans of right-sided iliac crests from female mice in each treatment group. External bone surface (left) is shown to visualise lytic lesions 
whilst the interior of the bone (right) enables assessment of trabecular integrity. B. Quantitation of total bone volume between groups. C. 
Quantitation of trabecular volume between treatment groups. Mice receiving the combination of bortezomib and K145 had an average total 
trabecular volume of 0.37±0.08 mm3 versus 0.23±0.04 mm3 in vehicle-treated animals (P = 0.003) and 0.28±0.08 mm3 in K145-treated 
animals (P = 0.045). However, there was only a trend towards greater trabecular volume compared to bortezomib treated mice, 0.37±0.08 
mm3 versus 0.31±0.09 mm3 in bortezomib-treated animals (P = 0.478). Six female mice were analysed per group with mean±SD shown.
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Dual K145 and bortezomib therapy reduces 
myeloma-associated bone disease
Myeloma results in the dysregulation of bone 
remodelling in favour of increased osteoclastic resorption 
resulting in many of the deleterious symptoms, including 
generalised bone loss, lytic bone lesions, hypercalcaemia 
and pathological fracture [1]. As bortezomib is known 
to reduce the number and severity of bone lytic lesions 
[36-38], we hypothesized that the addition of K145 to 
bortezomib would result in a further reduction in lytic 
lesions compared to either drug alone or vehicle. In mice 
receiving both drugs, micro CT analysis of the iliac crests, 
a region frequently infiltrated with myeloma according to 
bioluminescence images, showed reduced lytic lesions and 
greater trabecular integrity compared with other groups 
(Figure 8A and Supplementary Figure 10). However, 
no observable changes in total bone volume between 
treatment groups were evident (Figure 8B). Further 
analysis of trabecular volume demonstrated that mice 
receiving the combination of bortezomib and K145 had 
significantly greater total trabecular volume compared 
to vehicle control mice or mice treated with K145 alone 
(Figure 8C). A similar trend towards greater trabecular 
volume was also observed in combination treated mice 
compared to those treated with bortezomib alone, although 
this did not reach statistical significance (Figure 8C).
DISCUSSION
To date, most of the studies examining the role 
of the sphingosine kinases in cancer have focused on 
SK1 [39, 40]. However, studies have highlighted an 
emerging role for SK2 in haematological malignancies, 
including ALL [9-11]. A recent study by Venkata and 
colleagues [11] revealed a role of SK2 in myeloma 
disease pathogenesis and highlights SK2 as a potential 
therapeutic target. The subcellular localisation of SK2 to 
intracellular compartments, such as the ER and nucleus, 
suggest highly specialised roles for which ER membrane 
integrity and cell cycle regulation through S1P-induced 
inhibition of histone deacetylases have been reported [10, 
41, 42]. In this study, we examined the relevance of SK2 
in myeloma and show that inhibition of SK2 function 
can synergise with the clinically important proteasome 
inhibitor, bortezomib, to induce enhanced ER stress and 
UPR activation and attenuate myeloma cell growth and 
survival.
Perturbation of lipid metabolism, including the 
accumulation of ceramide species has been shown to 
induce ER stress and activate the UPR [23-25]. The 
de novo ceramide synthesis pathway occurs at the ER 
membrane so manipulation of this pathway can alter ER 
membrane sphingolipid homeostasis and contributes to 
ER stress [43-45]. However, these findings highlight the 
potential for a different mechanism of ER stress induction 
from that seen with proteasome inhibitors which result in 
the accumulation of misfolded proteins in the ER lumen, 
BiP dissociation from the lumenal domains of PERK, 
ATF6 and IRE1, chaperoning of misfolded proteins and 
activation of the UPR [7]. In keeping with this hypothesis, 
it has recently been shown that changes in the lipid 
composition of the ER membrane can directly activate 
IRE1 and PERK independently of lumenal unfolded 
proteins, to induce the UPR in a process that requires 
their transmembrane domains [46]. Our data show that 
K145 inhibition of SK2 results in increased ceramide 
species that, consistent with an ER membrane effect, does 
not significantly induce BiP expression but activates the 
PERK-eIF2α and IRE1-XBP1 pathways (Figure 5). This 
is in contrast to bortezomib, which results in strong BiP 
expression consistent with initiation of ER stress within 
the ER lumen. These different mechanisms leading to 
ER stress induced by bortezomib and K145 provide 
considerable rationale for concomitantly targeting both 
pathways in myeloma.
When used as single agents, or in combination, 
K145 and bortezomib induce JNK and p38MAPK 
activation, both components of well-established pro-
apoptotic signalling cascades. It has been shown that 
activation of the kinase domain of IRE1 is required for 
its endoribonuclease activity to splice XBP1 mRNA [21], 
however, IRE1 kinase activity also stimulates activation 
of tumour necrosis factor receptor associated factor 2 
(TRAF2) and apoptotic-signalling kinase-1 (ASK1) 
which, in turn, activate JNK and p38MAPK to induce 
apoptosis. [47] We have found that the IRE1-JNK pathway 
correlates with myeloma cell death induced by bortezomib 
or K145 and is markedly enhanced when both agents are 
used in combination. CHOP expression also increased 
markedly upon combining bortezomib with K145 
treatment. This observation, combined with the previous 
studies demonstrating that p38MAPK can activate CHOP 
via phosphorylation of its transactivation domain [48], 
suggests the potential for ER stress in myeloma cells to 
connect to the cellular apoptotic machinery through both 
the IRE1-JNK/p38MAPK pathway and PERK-eIF2α-
CHOP signalling, particularly in the context of SK2 
inhibition.
Combination therapy with bortezomib and K145 
was highly effective in the aggressive C57BL/KaLwRij 
5TGM1 murine myeloma model. Either drug alone 
produced only modest anti-myeloma effects after two 
weeks of treatment. However, the synergistic reduction 
in disease burden between animals receiving both 
drugs compared to single drug or vehicle was striking 
and suggests clinically relevant therapeutic potential 
for combination therapy with both bortezomib and an 
inhibitor of SK2. Furthermore, the reduction in lytic bone 
lesions and preservation of trabecular volume support 
the biological activity of this combination drug therapy, 
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though these findings warrant further detailed studies. 
Whether these effects are at least, in part, related to 
bone marrow microenvironmental changes are yet to be 
examined. 
Notably, our combination of K145 with bortezomib 
did not result in any obvious toxicity in mice. Furthermore, 
ongoing clinical trials with SK2 inhibitors have not 
reported any drug-related toxicities in humans [11], 
including neurotoxicity which is a common side-effect of 
bortezomib [49]. Indeed, in some contexts SK2 inhibition 
appears neuroprotective [50]. Thus, combining SK2 
inhibitors with bortezomib appears feasible in humans.
In summary, this study confirms that SK2 expression 
and activity are elevated compared to SK1 in myeloma 
cells and provides pre-clinical evidence for incorporating 
an inhibitor of SK2 into a proteasome inhibitor-containing 
combination drug therapeutic regimen. The tight control of 
ER stress in the myeloma cell also represents a potential 
weakness in its armoury, which is exploited by proteasome 
inhibitors and can be further enhanced by SK2 inhibition. 
Mechanistically, the importance of membrane lipids 
in contributing to ER stress levels and inducing UPR 
activation in myeloma cells has not been examined and 
represents a promising avenue of exploration that, in a 
biologically plausible manner, synergistically contributes 
to lumenal factors that initiate ER stress. More potent 
SK2 inhibitors and modulators of sphingolipid signalling 
are currently in development and are expected to further 
highlight the unappreciated role of sphingolipid biology in 




The human myeloma cell lines LP-1, NCI-H929, 
OPM2, U266, MM1.S, MM1.R, KMS-11, KMS-18, 
were grown in RPMI with 10% foetal calf serum, 100 U 
penicillin, 0.1 mg/mL streptomycin, 2 mM L-glutamine, 1 
mM pyruvate and 15 mM Hepes buffer in a humidified 5% 
CO2 atmosphere at 37oC. The 5TGM1 murine myeloma 
cell line, which constitutively expresses luciferase and 
GFP [31], was grown in IMDM with 20% foetal calf 
serum and otherwise identical conditions to the human 
myeloma cell lines.
Reagents, antibodies and western blotting
The SK2 inhibitors, K145 [17] and ABC294640 
[51], were purchased from Medkoo Biosciences (Chapel 
Hill, NC). Bortezomib (Janssen Cilag, New Brunswick 
NJ) was kindly provided by the Royal Adelaide Hospital 
Pharmacy Department. Luciferin was purchased from 
Biosynth (Lake Constance, Switzerland). Details of other 
reagents, antibodies and Western blotting are provided in 
Supplementary Methods.
Sphingolipidomics
Quantitation of sphingolipid species was performed 
at the Lipidomics Core Facility, Medical University of 
South Carolina, using previously described methods [52].
Proliferation and viability assays
Cell proliferation was measured using the WST-
1 reagent (Sigma-Aldrich). Briefly, 1 x 104 myeloma 
cells were plated in 100 µL culture medium (control) or 
varying concentrations of drug for 72 h after which 10 
µL of WST-1 reagent was added to each well for up to 
2 h and absorbance measured at 450 nM using a BiTek 
Epoch Microplate Spectrophotometer (Winooski, VT). 
Cell viability was measured using Annexin-V FITC and 
either PI or 7AAD staining as previously described [9] 
and analysed using a LSRFortessa flow cytometer (BD 
Biosciences).
Lentiviral SK2 shRNA
Details of the generation and transduction of the 
lentivirus encoding short hairpin RNA (shRNA) targeting 
SK2 are described in the Supplementary Methods.
Quantitative RT-PCR
Details of quantitative RT-PCR are provided in the 
Supplementary Methods.
In vivo myeloma model
Six to eight-week old C57BL/KaLwRij mice were 
inoculated with 1 x 106 5TGM1 cells by tail vein injection 
and disease allowed to develop for two weeks. Mice were 
then divided into four treatment groups: vehicle control, 
bortezomib alone, K145 alone and the combination of 
bortezomib and K145. K145 was administered daily 
at 20 mg/kg whilst bortezomib was administered three 
times per week at 0.5 mg/kg. Both drugs were given by 
intraperitoneal (IP) injection. Bioluminescence imaging 
after IP injection of 100 µL 30 mg/mL luciferin was 
performed at day 14 (prior to treatment), day 21 (after 
1 week of treatment) and day 28 (after two weeks of 
treatment). Mice were used with permission from the 
SA Pathology/Central Adelaide Local Health Network 
Animal Ethics committee (approval number 08a/14) and 
experiments were performed under the guidelines from 
Oncotarget43614www.impactjournals.com/oncotarget
the Australian code for the care and use of animals for 
scientific purposes, 8th edition, 2013. Details of micro CT 
analysis are provided in the Supplementary Methods.
Statistical analysis
Details of statistical analysis are provided in the 
Supplementary Methods.
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